	US 12,234,293 B2
	Treatment for primary amyloidosis with anti-BCMA binding protein
Sanjay Khandekar, Collegeville, PA (US); Patrick Mayes, Devon, PA (US); and Joanna Opalinska, Collegeville, PA (US)
Assigned to GlaxoSmithKline Intellectual Property Development Limited, Stevenage (GB)
Filed by GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED, Stevenage (GB)
Filed on Jun. 22, 2022, as Appl. No. 17/846,950.
Application 17/846,950 is a division of application No. 16/646,836, granted, now 11,401,334, previously published as PCT/IB2018/056967, filed on Sep. 12, 2018.
Claims priority of provisional application 62/558,575, filed on Sep. 14, 2017.
Prior Publication US 2023/0019140 A1, Jan. 19, 2023
Int. Cl. A61K 39/395 (2006.01); A61K 31/573 (2006.01); A61K 31/69 (2006.01); A61K 47/68 (2017.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); C07K 19/00 (2006.01); A61K 39/00 (2006.01); C07K 14/71 (2006.01)

CPC C07K 16/2878 (2013.01) [A61K 31/573 (2013.01); A61K 31/69 (2013.01); A61K 39/3955 (2013.01); A61K 39/39558 (2013.01); A61K 47/6817 (2017.08); A61P 35/00 (2018.01); C07K 16/2896 (2013.01); C07K 16/30 (2013.01); C07K 19/00 (2013.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); C07K 2317/56 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2319/55 (2013.01)]

19 Claims

1. A method of treating primary amyloidosis (AL) in a subject in need thereof, the method comprising: administering to the subject in need thereof a dose of 1.9 mg/kg or 2.5 mg/kg of an anti-B-cell maturation antigen (BCMA) antibody conjugated to monomethyl auristatin F (MMAF), wherein the anti-BCMA antibody comprises a heavy chain comprising the amino acid sequence set forth in SEQ ID NO:9 and a light chain comprising the amino acid sequence set forth in SEQ ID NO:10.